Antibody Drug Conjugates (ADC) Market

The antibody drug conjugates market is projected to reach USD 19.8 Billion by 2028 from USD 9.7 Billion in 2023, at a CAGR of 15.2% during the forecast period. Growth in the antibody drug conjugates market can be attributed to factors such as the collaborations and partnerships among market players for the development of new ADCs, and the rising number of government approvals for antibody drug conjugates.

The global antibody drug conjugates market is highly competitive. The prominent players operating in this market include F. Hoffmann-La Roche Ltd (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US),  and Zydus Group (India), among others.

To know about the assumptions considered for the study download the pdf brochure

F. Hoffmann-La Roche Ltd (Switzerland)

In 2022, F. Hoffmann-La Roche Ltd. held a dominant position in the market. F. Hoffmann-La Roche Ltd. offers a strong product portfolio in antibody drug conjugate. The company has a diversified geographic reach and a strong emphasis on research and development. The company’s product revenue for Kadcyla and Polivy increased by 0.5% and 69.5% respectively in 2022 compared to 2021. Strong emphasis on investment in clinical trials and currently various products under pipeline which are likely to be launched in the coming 3-5 years has a strong impact on the company’s market position.

Daiichi Sankyo Company, Limited (Japan)

Daiichi Sankyo Company, Limited held the leading position in the market in 2022. The company has a diversified geographic reach and a strong emphasis on research and development. The company’s product revenue in Enhertu doubled in 2022 compared to 2021. A strong emphasis on investment in clinical trials and collaboration with leading market players for product development is likely to uplift the market rank of the company. A strong focus on approvals of the product in various regions is one of the strategies adopted by the company to maintain a dominant position in the market. For instance, in April 2023, Daiichi Sankyo received approval in Japan for ENHERTU for the treatment of adult patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 (ERBB2) mutations that have progressed after chemotherapy.

Seagen Inc. (US)

Seagen is a biotechnology company known for its expertise and innovation in the antibody-drug conjugate (ADC) market. The key strengths that contributed to Seagen's prominence in the ADC market include a strong pipeline of product candidates and proprietary auristatin-based ADC technology. Seagen’s most advanced commercial and clinical ADCs portfolio including ADCETRIS, PADCEV, TIVDAK, disitamab vedotin, and ladiratuzumab vedotin, use proprietary auristatin-based ADC technology. Seagen is also developing SGN-B7H4V, an ADC which is in phase 1 clinical trial for certain solid tumors including breast, endometrial and ovarian cancer.

Related Reports:

Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, Region - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]